Day: June 23, 2025

Sarclisa recommended for EU approval by the CHMP to treat transplant-eligible newly diagnosed multiple myelomaRecommendation based on GMMG-HD7 phase 3 study demonstrating that Sarclisa with VRd induction treatment significantly improved MRD negativity benefit and prolonged PFS compared to VRd alone If approved, it would represent the fourth indication in the EU and second in the front-line setting globallyParis, June 23, 2025. The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of Sarclisa in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for the induction treatment of adult patients with newly diagnosed multiple myeloma (NDMM) who are eligible for autologous stem cell transplant. A final decision is expected in the coming...

23 June 2025, Limassol, Cyprus / Ad hoc announcement pursuant to Art. 53 LR We have been notified that, Aurora Value Fund, a fund organized and existing under the laws of Liechtenstein, registered with the Liechtenstein Investment Fund Association (LAFV) under register number FL-0002.305.581-2 represented and acting through its management company CAIAC Fund Management AG, a company incorporated under the laws of Liechtenstein, with registered office at Haus Atzig, Industriestrasse 2, 9487 Bendern, Liechtenstein as part of a fund liquidation contributed in kind 59.94% of the voting rights in EPH European Property Holdings PLC  by contributing 8,636,897 shares to several investors. The transaction was executed on 16th June 2025, and the notification was duly submitted to the Disclosure Office of SIX Exchange Regulation. The Company has been...

Ad hoc announcement pursuant to Art. 53 LRIdorsia to receive USD 50 million (an additional USD 30 million) approval milestone payment in return for a reduction in Simcere potential sales milestones and tiered royalty payments.Allschwil, Switzerland – June 23, 2025Idorsia Ltd. (SIX: IDIA) today announced that Simcere Pharmaceuticals Group Ltd (2096.HK, “Simcere”) has received approval for QUVIVIQ® (daridorexant) from the Chinese National Medical Products Administration for the treatment of adult patients with insomnia characterized by difficulty falling asleep and/or maintaining sleep, with no psychotropic drug control labeling. In addition, Idorsia has reached an agreement with Simcere to update the terms of the licensing agreement for QUVIVIQ in China. André C. Muller, Chief Executive Officer of Idorsia, commented:“I want to congratulate...

Basel, June 23, 2025 – Novartis today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), in connection with Novartis’ previously announced tender offer to acquire all of the outstanding shares of common stock, par value $0.001 per share (the “Shares”), of Regulus Therapeutics Inc. (“Regulus”), in exchange for (i) $7.00 in cash per Share, subject to any applicable withholding and without interest thereon, plus (ii) one contingent value right (each, a “CVR”) per Share, representing the right to receive one contingent payment of $7.00 in cash, subject to any applicable withholding and without interest thereon, upon the achievement of a regulatory milestone. The expiration of the HSR Act waiting period occurred at 11:59 p.m., New York City Time, on June...

IRVINE, Calif., June 23, 2025 (GLOBE NEWSWIRE) — SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical”), a global franchise and provider of services for aesthetic clinics, recently participated in several prominent investor conferences throughout May and June 2025. SBC Medical delivered webcast presentations and conducted one-on-one meetings with institutional investors. Presentation videos can be viewed at the links below:https://youtu.be/sM8VzxrQpac?feature=shared Below is a summary of the Company’s participation in recent investor conferences:Zacks SCR Life Sciences Virtual Investor ForumMain Speaker: Yuya Yoshida (CFO)Date: June 12, 2025Sidoti Small-Cap Virtual ConferenceMain Speaker: Yuya Yoshida (CFO)Date: June 11, 2025Noble Capital Markets’ Emerging Growth Virtual Equity ConferenceMain Speaker:...